Skip to main content
. 2017 Jul 28;8(41):70508–70520. doi: 10.18632/oncotarget.19733

Figure 5. Validation of COL3A1.

Figure 5

(A) COL3A1 expression was correlated with the disease progression of BCa (GSE13507). (B) and (C) Oncomine database indicated that COL3A1 was up-regulated in BCa, compared with normal bladder, as well as up-regulated in infiltrating bladder urothelial carcinoma, compared with superficial bladder cancer. (D) COL3A1 mRNA was validated using 13 BCa tissues and matched paracancerous tissues by qRT-PCR (p < 0.01). (E) The human protein atlas database indicated the elevated expression of COL3A1 in BCa tissue compared with normal bladder tissue on translational level. (The normal urinary bladder tissue was from a female, aged 79 (Patient id: 3265; staining: low; intensity: moderate; quantity: < 25%; location: cytoplasmic/membranous) and the bladder cancer tissue was from a female, aged 56 (Patient ID: 3077; staining: medium; intensity: moderate; quantity: 75% - 25%; location: cytoplasmic/membranous) (F) GEPIA database indicated that COL3A1 had a strong correlation with the progression of BCa based on TCGA data. (G-H)Kaplan-Meier survival curve obtained GEPIA database revealed that BCa patients with higher expression of COL3A1 had a significantly shorter (G) overall survival time and (H) disease free survival time.